Overview

Individually Adapted Therapy of Alcoholism

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The primary objective is to directly compare the efficacy of acamprosate, naltrexone and placebo for relapse prevention in alcoholics.
Phase:
Phase 4
Details
Lead Sponsor:
Central Institute of Mental Health, Mannheim
Collaborators:
Dupont Applied Biosciences
German Federal Ministry of Education and Research
Merck Sharp & Dohme Corp.
Treatments:
Acamprosate
Naltrexone